Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zanamivir
Drug ID BADD_D02380
Description A guanido-neuraminic acid that is used to inhibit neuraminidase.
Indications and Usage For the prevention and treatment of influenza A and B.
Marketing Status approved; investigational
ATC Code J05AH01
DrugBank ID DB00558
KEGG ID D00902
MeSH ID D053243
PubChem ID 60855
TTD Drug ID D00NPP
NDC Product Code 0173-0681; 63379-028
UNII L6O3XI777I
Synonyms Zanamivir | 2,3-Didehydro-2,4-Dideoxy-4-Guanidinyl-N-Acetylneuraminic Acid | 4-Guanidino-2,4-Dideoxy-2,3-Didehydro-N-Acetylneuraminic Acid | 5-Acetylamino-2,6-Anhydro-4-Guanidino-3,4,5-Trideoxy-D-Galacto-Non-Enoic Acid | 4-Guanidino-Neu5Ac2en | 4 Guanidino Neu5Ac2en | 2,3-Didehydro-2,4-Dideoxy-4-Guanidino-N-Acetyl-D-Neuraminic Acid | 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic Acid | 4 Guanidino 2 Deoxy 2,3 Didehydro N Acetylneuraminic Acid | Acid, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic | Relenza | GG 167 | GG167 | GG-167
Chemical Information
Molecular Formula C12H20N4O7
CAS Registry Number 139110-80-8
SMILES CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Screaming19.04.02.020; 08.01.03.0990.002145%Not Available
Seizure17.12.03.0010.002456%
Shock24.06.02.002--Not Available
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.0060.000282%
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Supraventricular tachycardia02.03.03.0120.000282%
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000282%
Therapeutic response decreased08.06.01.0160.000282%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Unresponsive to stimuli17.02.05.0310.000423%Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.0070.000423%
Visual impairment06.02.10.0130.000423%Not Available
Vomiting07.01.07.0030.000847%
Musculoskeletal stiffness15.03.05.0270.000282%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.000423%Not Available
Eyelid disorder23.03.03.028; 06.08.03.0100.000282%Not Available
Abnormal behaviour19.01.01.0010.004685%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.000847%
Ill-defined disorder08.01.03.049--Not Available
Nasal disorder22.04.03.004--Not Available
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Oral mucosa erosion07.05.06.0090.000282%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000282%
Acute kidney injury20.01.03.0160.000847%
Rheumatic disorder10.02.01.048; 15.03.04.018--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages